BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10435586)

  • 21. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP.
    Izutsu K; Kurokawa M; Imai Y; Ichikawa M; Asai T; Maki K; Mitani K; Hirai H
    Oncogene; 2002 Apr; 21(17):2695-703. PubMed ID: 11965542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An acute myeloid leukemia gene, AML1, regulates transcriptional activation and hemopoietic myeloid cell differentiation antagonistically by two alternative spliced forms.
    Tanaka T; Tanaka K; Ogawa S; Kurokawa M; Mitani K; Yazaki Y; Shibata Y; Hirai H
    Leukemia; 1997 Apr; 11 Suppl 3():299-302. PubMed ID: 9209372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation.
    Lindberg SR; Olsson A; Persson AM; Olsson I
    Exp Hematol; 2005 Feb; 33(2):189-98. PubMed ID: 15676213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
    Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line.
    Zhuang WY; Cen JN; Zhao Y; Chen ZX
    Oncol Rep; 2013 Jul; 30(1):185-92. PubMed ID: 23673926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
    Peterson LF; Lo MC; Okumura AJ; Zhang DE
    Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.
    Yergeau DA; Hetherington CJ; Wang Q; Zhang P; Sharpe AH; Binder M; Marín-Padilla M; Tenen DG; Speck NA; Zhang DE
    Nat Genet; 1997 Mar; 15(3):303-6. PubMed ID: 9054947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).
    Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y
    Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3.
    Khanna-Gupta A; Lopingco MC; Savinelli T; Zibello T; Berliner N; Perkins AS
    Oncogene; 1996 Feb; 12(3):563-9. PubMed ID: 8637713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of bcl-2 homologs in human CD34(+) hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells.
    Josefsen D; Myklebust JH; Lømo J; Sioud M; Blomhoff HK; Smeland EB
    Stem Cells; 2000; 18(4):261-72. PubMed ID: 10924092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation.
    Peterson LF; Wang Y; Lo MC; Yan M; Kanbe E; Zhang DE
    Leukemia; 2007 Sep; 21(9):2010-9. PubMed ID: 17657222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8.
    Matsushita H; Kizaki M; Kobayashi H; Muto A; Ikeda Y
    Br J Cancer; 1999 Mar; 79(9-10):1325-31. PubMed ID: 10188872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-myb alters the response of myeloid precursor cells to G-CSF.
    Engelhard A; Campbell K; Calabretta B
    Exp Cell Res; 2000 Jan; 254(1):153-62. PubMed ID: 10623475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.
    Lausen J; Liu S; Fliegauf M; Lübbert M; Werner MH
    Oncogene; 2006 Mar; 25(9):1349-57. PubMed ID: 16247445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal.
    Tonks A; Tonks AJ; Pearn L; Pearce L; Hoy T; Couzens S; Fisher J; Burnett AK; Darley RL
    Leukemia; 2004 Jul; 18(7):1238-45. PubMed ID: 15152269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1.
    Choi Y; Elagib KE; Delehanty LL; Goldfarb AN
    Cancer Res; 2006 Mar; 66(6):2990-6. PubMed ID: 16540647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells.
    Britos-Bray M; Sacchi N; Friedman AD
    Leukemia; 1996 Jun; 10(6):984-90. PubMed ID: 8667656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of a pluripotent preleukaemic stem cell line by expression of the AML1-ETO fusion protein in Notch1-immortalized HSCN1cl10 cells.
    Delaney C; Bernstein ID
    Br J Haematol; 2004 May; 125(3):353-7. PubMed ID: 15086416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of the AML1-ETO fusion transcript expression in children and young adults with t(8;21) acute myeloid leukemia.
    Fleischman EW; Baturina JA; Sokova OI; Popa AV; Kosorukova IS; Rowley JD
    Haematologica; 2003 Sep; 88(9):1078-9. PubMed ID: 12969821
    [No Abstract]   [Full Text] [Related]  

  • 40. Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias.
    Wang J; Wang M; Liu JM
    Cancer Res; 1997 Jul; 57(14):2951-5. PubMed ID: 9230207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.